NCT06894225

Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: National Neuroscience Institute · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

This trial will study the effectiveness of ACT001 in adult patients whose Glioblastoma have recurred with a STAT3-high signature after standard-of-care treatment with at least radiation therapy.

Conditions

• Recurrent Glioblastoma

Interventions

Type	Name	Description
DRUG	ACT001	Patients recruited and have signed informed consent will be initiated on ACT001 400mg twice a day. Treatment course will repeat every 28 days in the absence of disease progression or unacceptable toxicity

Timeline

• Start date: 2025-04-01
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2025-03-25
• Last updated: 2025-04-06

Locations

1 site across 1 country: Singapore